Skip to main content
Premium Trial:

Request an Annual Quote

A Thief in the Night?

Premium

Craig Thompson, the CEO and president of the Memorial Sloan-Kettering Cancer Center, is being accused of taking research belonging to a University of Pennsylvania cancer institute and using it to start a pharmaceutical company, reports Pharmalot's Ed Silverman. The Abramson Family Cancer Research Institute at the University of Pennsylvania — where Thompson was a faculty member from 1999 until 2010 — says Thompson did not honor an agreement stating that any scientific discoveries made there belongs to the institute and thus has made $110 million so far from intellectual property that doesn't belong to him. "His work at the Institute involved developing a cancer metabolism research platform that was designed to examine the role that metabolic changes play in the origins, progression and death of cancer cells," Silverman says. "However, Thompson later co-founded Agios Pharmaceuticals, which was focused on researching cancer metabolism to develop new treatments." The institute says Thompson has caused about $1 billion in damages, and has included Agios in its lawsuit. Thompson did not comment to Silverman.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.